Objectives: To evaluate the efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed Mongolian gerbil (Meriones unguiculatus) model.
Introduction
In cryptosporidiosis patients, cholangiopathy may result from biliary Cryptosporidium sp. infection, the most common extraintestinal site. 1 In immunodeficient subjects with persistent cryptosporidiosis, including patients with the X-linked immunodeficiency with hyper-IgM, acalculous cholecystitis, sclerosing cholangitis or both may develop. 2, 3 In one study, 70% of children with X-linked immunodeficiency with hyper-IgM who were systematically screened microscopically for infection exhibited Cryptosporidium parvum infection and all had clinically significant chronic liver disease. 4 In patients with primary immunodeficiency, PCR procedures were found to be more sensitive than microscopy to detect Cryptosporidium infection. 5 Cryptosporidium sp. was identified in the bile or intestine of 20-65% of patients with AIDS-associated cholangiopathy with sclerosing cholangitis leading to biliary cirrhosis and ultimately to liver failure and/or cholangiocarcinoma. 1, 3 In AIDS cholangiopathy patients, the presence of cryptosporidial infection at the time of diagnosis was found to be an indicator of poor prognosis. 6 Recently, chronic gastrointestinal and extra-intestinal cryptosporidiosis with secondary sclerosing cholangitis has been reported in a child in the absence of an associated immunodeficiency. 7 Biliary carriage represents a reservoir for intestinal cryptosporidiosis relapse which is not prevented by luminal agents such as paromomycin. 8 The aim of this study was to evaluate the efficacy of nitazoxanide, a 2-acetyloxy-N-[ Materials and methods
C. parvum oocysts
Oocysts were purified from faeces obtained from calves experimentally infected by an isolate maintained by Drs Mancassola and Naciri, Laboratoire de Pathologie Aviaire, Institut National de Recherche Agronomique, Nouzilly, France, and confirmed as C. parvum.
10 Viable (>80% excluding propidium iodide) oocysts were purified from faecal samples as earlier described, and stored in phosphate-buffered saline (PBS), pH 7.2, at 4 C for <3 months before use.
11
Agents A powdered form of nitazoxanide was obtained from Romark Laboratories, Tampa, FL, USA. Paromomycin was purchased from Sigma, St Louis, MO, USA. Agents were suspended in a 5% carboxymethylcellulose solution in water.
Immunosuppressed gerbils
Gerbils (4-5 weeks old; 22-27 g) free of Cryptosporidium sp. oocysts before the study were individually housed in plastic cages providing heat-sterilized rodent food and water ad libitum and protected by a top filter. Animals were handled according to the technical and ethical regulations of the French Ministry of Agriculture and this project was approved by the ethics committee of ADEN. From 10 days before the day of oocyst ingestion (day 0) to day 12, gerbils were intraperitoneally injected with 0.80 mg/animal dexamethasone (Qualimed, Puteaux, France) every second day.
Assessment of nitazoxanide and paromomycin anticryptosporidial activities in immunosuppressed gerbils
On day 0, gerbils were gavaged with 10 5 C. parvum oocysts and divided into groups administered orally on the same day 10 mL/kg of a 5% carboxymethylcellulose water solution with nitazoxanide (100 mg/kg) (n = 14), paromomycin (50 mg/kg) (n = 15) or no agent (control group, n = 16) twice daily for 12 days. These regimens were adapted from previous studies in immunosuppressed rats.
12,13
Faeces were collected on days 4, 8 and 12 post-infection from each gerbil, and pooled. Faecal smears were microscopically examined using Heine staining and 24 h shedding was expressed as mean blind oocyst count per 10 phase contrast microscopic field (MF) (·400 magnification) from 30 MF by two independent investigators. All animals were killed 12 days post-infection by deep pentothal anaesthesia and necropsied. Distal ileal segments and biliary tracts fixed in 10% formalin were cut, embedded in paraffin for blind histological examination of 4 mm sections stained with haematoxylineosin-saffron and Giemsa, and considered infected if at least one cryptosporidial developmental form was microscopically observed within an epithelial cell by two independent investigators.
Statistical analysis
Comparison of intestinal oocyst shedding between groups was performed using the Willcoxon's rank sum test. Comparisons of the effects on ileal and gall bladder mucosa infection were performed using Fisher's exact tests.
Results
As shown in Table 1 , a significant decrease in oocyst shedding was observed in treated animals with the same magnitude for nitazoxanide and paromomycin (P > 0.05). As shown in Table 2 , the number of animals with infected ileum and/or gall bladder was lower in the nitazoxanide group than in the untreated group. In contrast, no significant decrease in the number of animals with infected gall bladder was found in the paromomycin-treated group (P > 0.05).
Discussion
In humans, biliary involvement due to cryptosporidiosis was documented in immunodeficient patients including HIV-infected individuals and patients with the X-linked hyper-IgM syndrome.
14 In most animal models, infection was limited to the intestine during acute cryptosporidiosis. 11, 12 The biliary system was found to be involved in immunosuppressed chronically infected animals and usually not established before 4-5 weeks post-intestinal oocyst challenge. In the present protocol, Mongolian gerbils infected 10 days after the initiation of immunosuppression exhibited biliary cryptosporidiosis as assessed by gall bladder histological examination on day 12 post-infection. When administered 4 h after infection, nitazoxanide and paromomycin at doses previously shown to be effective on gut infection in rats and neonatal mice prevented the establishment of developmental stages in the intestinal tract.
12, 13, 15 Nitazoxanide exerted a more significant anticryptosporidial activity in the gall bladder than paromomycin, consistent with previous studies in other rodent models in which paromomycin exhibited limited effectiveness against biliary tract infection. Similarly, AIDS patients developed biliary tract infections during their treatment with paromomycin. 8 Paromomycin was not absorbed by the human gut, in contrast with orally administered nitazoxanide whose metabolite tizoxanide glucuronide was found to be excreted in the biliary tract. 8, 16 Tizoxanide glucuronide was previously shown to exhibit predominantly its in vitro anticryptosporidial activity on intracellular parasitic forms, which may relate to the activity of nitazoxanide in vivo. 17 Present data prompt further studies to determine if nitazoxanide has clinical activity in human cryptosporidial cholangitis.
